Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05398133

Enrollment

Registered

2022-05-31

Start date

2020-09-01

Completion date

2022-06-30

Last updated

2022-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Asthma, Eosinophilic Asthma

Keywords

eosinophil, COPD, asthma

Brief summary

Around 1/3 of patients with COPD have elevated eosinophil levels. However, the role of eosinophils in COPD has not been yet understood and is probably different in COPD and in asthma. The aim of this study was to assess the expression of selected surface markers on eosinophils and to assess the gene expression in eosinophils in COPD and asthma patients. We are planning to enrol 12 COPD, 12 asthma and 12 control subjects. Patients will undergo routine clinical assessment, spirometry, blood sampling and sputum induction. Eosinophils will be isolated from blood and sputum. Surface markers on eosinophils will be assessed in flow cytometry, gene expression will be assessed by RNAseq.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosis of COPD according to GOLD 2019 or asthma according to GINA 2021 * Peripheral blood eosinophil count ≥ 100 / μL * Age ≥40 years (COPD), ≥18 years (asthma) * History of cigarette smoking: ≥10 pack-years (for COPD) * Stable disease period (at least 3 months without exacerbation) * Exclusion of parasitic diseases * Informed consent to participate in the study

Exclusion criteria

* COPD and asthma overlap * Use of systemic corticosteroids in the 3 months prior to the study * Respiratory infection or exacerbation in the 3 months prior to the study * Acute and chronic respiratory failure * Concomitant diagnoses: systemic connective tissue diseases, malignant neoplasms, severe and / or uncontrolled cardiovascular diseases * Use of immunosuppressive or immunomodulating drugs in the 3 months preceding the study * Contraindications to sputum induction * No consent to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
expression of surface markers	performed up to 3 months after blood and sputum collection	expression of CD125, CD62L, CD66b, CD193, CD11b, CD14

Countries

Poland

Contacts

Primary ContactKatarzyna Gorska, MD PhD

drkpgorska@gmail.com22 599 27 53

Outcome results